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Effects of lycopene on plasma glucose, insulin levels, oxidative
stress, and body weights of streptozotocin-induced diabetic rats
Muhsin AYDIN, Sefa ÇELİK

Aim: To determine possible therapeutic effects of oral lycopene supplementation on plasma insulin levels, lipid
peroxidation, blood glucose levels, and the antioxidant defense system of streptozotocin-induced diabetic rats.
Materials and methods: Classical biochemical methods were used to determine plasma malondialdehyde (MDA), nitric
oxide (NO), glutathione peroxidase (GSH-Px), catalase (CAT), superoxide dismutase (SOD), and glutathione (GSH)
levels. Enzyme-linked immunosorbent assay was used to determine plasma insulin levels and reverse transcriptasepolymerase chain reaction was used to determine the levels of brain antioxidant enzymes (SOD, CAT, and GSH-Px).
Results: It was found that the diabetes-related increase in blood glucose levels was reduced by supplementation of
lycopene over an 8-week period. Plasma NO levels and brain tissue GSH levels were meaningfully reduced in the
treatment group compared to the diabetic group. In the hemolysate samples, it was determined that the treatment
group’s SOD, CAT, and GSH-Px activities significantly increased compared to the diabetic group. In the brain tissue
homogenates, CAT and SOD activity did not show a significant change, whereas GSH-Px activity was increased in the
treatment group compared to the diabetic group. SOD, CAT, and GSH-Px mRNA transcription levels were suppressed in
the diabetic group compared to the control, and this suppression was stopped and increases were significantly induced
by the supplementation of lycopene.
Conclusion: In this study, the oxidative damage and low insulin levels associated with diabetes were ameliorated with
the administration of lycopene. The results of this study indicate that lycopene is an effective nutritional component to
alleviate and/or prevent the complications of diabetes, and these findings can be used as a basis for future studies.
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Introduction
Diabetes mellitus is a chronic metabolic disorder
and its incidence has been increasing all around
the world. Several mechanisms are involved in the
pathogenesis of diabetes and its complications. The
most commonly accepted cause of diabetes is the
oxidative damage that is caused by free radicals (1).
Recent studies showed an increasing use of
medicinal plants or their extracts to ameliorate
diseases (2,3). Lycopene is commonly found in many
foods in nature. In this study, the effects of lycopene
for overcoming oxidative damage in diabetes, which

plays an important role in the development of
diabetes, was investigated. The preventive effects of
lycopene were also examined on diabetic disorders
such as body weight loss, decreased insulin levels,
and decreased plasma glucose levels.
Free radicals play an important role in plasma
chemistry, biochemistry, and many other chemical
processes within the human physiology (4). Free
radical damage could be a reason for many diseases,
including diabetes (5). When the number of free
radicals increases to the point that they outnumber
the antioxidants, they can attack the somatic cells
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and immune system (6). Antioxidants are molecules
that neutralize the effects of free radicals by donating
an electron to pair with the free radical’s unpaired
electrons. Healthy people have a balance between free
radicals and antioxidants. However, it has been shown
that people who have diabetes have higher levels of
free radicals, which can cause diabetic complications
(7). During diabetes, persistent hyperglycemia causes
an increased production of free radicals, especially
reactive oxygen species (ROS), for all tissues from
glucose autoxidation and protein glycosylation (8,9).
Damage of cellular organelles and enzymes and an
increase in lipid peroxidation can be caused by high
levels of free radicals and the simultaneous decline of
antioxidant defense mechanisms (1,10,11).
Carotenoids have protective effects against
chronic diseases, which are thought to be caused
by damage from free radicals. Carotenoids prevent
oxidative damage in biological systems, such as
damage to the cell membrane, DNA molecules, lipids,
proteins, and other structures in the cell. Lycopene is
a nonprovitamin A carotenoid with an open chain
structure that has 11 linearly arranged conjugated
double bonds. The antioxidant activity of lycopene is
somewhat higher than that of β-carotene, but it is not
present in as many foods as β-carotene (11). Lycopene
is mainly found in red fruits and vegetables, such as
watermelons, tomatoes, pink grapes, and apricots
(12).
The overall objective of this research project was to
investigate the possible antidiabetic and therapeutic
effects of lycopene on diabetes in streptozotocin
(STZ)-induced diabetic rats. The specific aims of the
study were: 1) to investigate the effect of lycopene
supplementation on blood glucose concentration,
body weight, lipid peroxidation, and plasma insulin
levels; 2) to investigate nitric oxide (NO), glutathione
(GSH), and malondialdehyde (MDA) levels and the
antioxidant enzyme [superoxide dismutase (SOD),
catalase (CAT), and glutathione peroxidase (GSHPx)] levels in both blood and brain tissue samples;
3) and to investigate the effect of lycopene on the
expression of the antioxidant enzyme genes (SOD,
CAT, and GSH-Px) that regulate the antioxidative
defense mechanisms in brain tissues.

Materials and methods
Animal model and sample preparation
Twenty-four male Wistar rats (n = 6 per group), 2
months of age and weighing between 150 and 250 g,
were allocated randomly and equally as control (C),
diabetic (D), lycopene-supplemented diabetic (D +
L), and lycopene-supplemented control (L) groups.
For this study, permission was issued by the ethical
committee of Mustafa Kemal University.
After overnight fasting, diabetes was induced
in the rats by a single intraperitoneal injection of
STZ (Sigma) at a dose of 45 mg/kg. The STZ was
dissolved in 0.1 M cold sodium citrate buffer, pH
4.5 (13). The rats were allowed to drink a 5% glucose
solution overnight to overcome the drug-induced
hypoglycemia. Plasma glucose levels were measured
with an Accu-Check Go strip test in a glucometer.
Blood sugar levels were measured before and after
48 h of STZ induction. After 48 h of STZ induction,
the rats whose blood glucose levels were ≥300 mg/
dL were considered as diabetic. The rats of the
control and diabetic groups were fed without any
supplements except sunflower oil, which was used for
dissolving the lycopene, while 4 mg/kg body weight
of lycopene was administrated orally, daily, to the
diabetic + lycopene group and the lycopene group for
8 weeks. The dose of lycopene that was used in this
study was selected on the basis of previous studies
(11,14). Plasma glucose levels and the body weights
of the animals were measured weekly for the duration
of the study.
The lycopene was suspended in sunflower oil and
administered to the rats at a dose of 4 mg/kg body
weight, once a day for 8 weeks. The control and
diabetic rats received the same volume of sunflower
oil. The diabetic + lycopene and the lycopene control
rats were given the same volume of lycopene. The
rats were anesthetized by an intramuscular injection
of 50 mg/kg of ketamine, and blood was taken
by puncturing the heart ventricle at the end of the
experiment. Blood samples were centrifuged at
3000 rpm for 20 min and the plasma was separated.
Red blood cells that remained on the bottom of the
tubes were washed with a phosphate buffer, pH 7.4,
and the samples were then kept at –20 °C until they
were analyzed. The hemoglobin concentrations of
the erythrocytes were measured using the method
described by Drabkin (15).
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MDA, CAT, SOD, GSH-Px, and NO assays
The brains were removed from each rat, washed with
an ice-cold physiological saline (PBS) buffer of pH 7.0
containing protease inhibitor (Pi) mixture (Sigma),
and used for biochemical studies. Tissue samples
were homogenized in an ice-cold PBS buffer, pH 7.0,
containing a complete Pi mixture. The homogenates
were centrifuged at 4 °C at 15,000 rpm for 20 min,
and the soluble fraction was retained. The protein
concentrations of the supernatants were measured
using the method described by Bradford (16), using
bovine serum albumin as a standard. The degree of
lipid peroxidation was assessed by measuring the
MDA levels in the plasma and brain tissue samples
(17). CAT enzyme activity in the red blood cells
and homogenates was measured using the speed
reduction of hydrogen peroxidase (18). Total SOD
activity in the homogenates and plasma samples
was determined according to the method of Sun
et al. (19). The reduced GSH concentrations in the
homogenates and plasma samples were determined
according to the method of Sedlak and Lindsay (20).
The NO concentration in the plasma and brain tissue
samples (homogenates) was determined indirectly
by measuring the nitrite levels based on the Griess
reaction (21). The GSH-Px activity in the erythrocytes
and homogenates was measured according to the
method of Paglia and Valentine (22). Blood plasma
insulin levels were measured with the enzyme-linked
immunosorbent assay (ELISA).
mRNA extraction and RT-PCR
In the brain tissues, the mRNA expression levels of
the antioxidant enzymes (CAT, SOD, and GSH-Px)

were determined by reverse transcriptase-polymerase
chain reaction (RT-PCR). The RNA was isolated using
TRI Reagent (Sigma). The RNA’s purity was then
checked by spectrophotometer with 260-nm and 280nm filters. The RNA having a 260/280 measurement
of ≥1.8 was studied. Moreover, to ensure the presence
of RNA, the RNA structures were observed under an
ultraviolet (UV) light that was run in 1% agarose
gel (electrophoresis). From each sample, 1 µg of
RNA was taken and complementary DNA (cDNA)
was produced using reverse transcriptase. Next, Taq
polymerase, buffers, and oligonucleotides (primers)
were added to 1-µL cDNA samples. Primers were
specific for each PCR and 100 ng per sample was
used. The base sequences and their product sizes are
given for each primer, GSH-Px (23), CAT, and SOD
(24) in Table 1. β-Actin was used as a housekeeping
(control gene) primer (25). PCR amplification was
done using a thermal cycler. Before the PCR products
were captured under the UV light, they were run in
1.5% agarose gel. The digital photos were assessed
with the DigiDoc-It image analyzer program. The
mRNA transcription levels were determined by
performing normalization of the control gene. The
data were analyzed using SPSS 9.05 for Windows for
one-way ANOVA and post hoc multiple comparison
tests.
Results
Beginning from week 5, a significant diabetes-related
decrease (P < 0.05) in body weight was observed, but
lycopene administration had no significant effect

Table 1. The primers used in the PCR and PCR conditions (F: forward primer, R: reverse primer).

Gene

Primers

Product (bp)

PCR program

Cycles

β-Actin

F-CATCGTCACCAACTGGGACGA
R-CGTGGCCATCTCTTGCTCGAAG

466

Initial: 95 °C, 10 min / annealing: 95 °C, 1 min – 55
°C, 70 s – 72 °C, 100 s / final: 72 °C, 10 min

35

GSH-Px

F-CTCTCCGCGGTGGCACAGT
R-CCACCACCGGGTCGGACATAC

290

Initial: 94 °C, 5 min / annealing: 94 °C, 30 s – 60
°C, 60 s – 72 °C, 30 s / final: 72 °C, 5 min

32

CAT

F-GGCAGCTATGTGAGAGCC
R-CTGACGTCCACCCTGACT

116

Initial: 94 °C, 5 min / annealing: 94 °C, 30 s – 55
°C, 30 s – 72 °C, 15 s / final: 72 °C, 5 min

35

SOD

F-GTTCCGAGGCCGCCGCGCGT
R-GTCCCCATATTGATGGAC

192

Initial: 94 °C, 5 min / annealing: 94 °C, 30 s – 55
°C, 30 s – 72 °C, 20 s / final: 72 °C, 5 min

35
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Table 2. Effects of lycopene supplementation on the change of body weight (g) in rats (mean ± standard error).
Week

Control group

Diabetic group

Diabetic group + lycopene

Lycopene group

1

134.33 ± 2.82

143.60 ± 8.80

140.40 ± 2.99

148.00 ± 3.07¥,#

2

144.67 ± 2.59

143.20 ± 7.42

137.80 ± 1.96

159.67 ± 3.88¥,#

3

146.33 ± 3.02

140.40 ± 7.90

134.00 ± 2.55

163.50 ± 3.18¥,#

4

147.67 ± 3.07

139.60 ± 5.61

135.20 ± 2.03¥

170.00 ± 2.86*,#

5

153.83 ± 2.73

139.20 ± 6.72

¥

133.20 ± 2.58

170.67 ± 2.75¥,#

6

159.33 ± 2.29

130.20 ± 7.17*

130.20 ± 2.76*

174.50 ± 2.88¥,#

7

161.50 ± 3.02

132.00 ± 7.01*

131.80 ± 2.76*

178.50 ± 2.49¥,#

8

170.00 ± 2.93

137.40 ± 6.02*

135.60 ± 0.68*

184.17 ± 2.55¥,#

¥

*P < 0.001, ¥P < 0.05 compared to the control. #P < 0.05 compared to the STZ-diabetic group.

on body weight loss (Table 2). The blood glucose
levels significantly (P < 0.001) increased as a result of
diabetes in the diabetic group, which was suppressed
by the lycopene administration during the 8-week
period in the treatment group (Table 3). The plasma
and brain tissue GSH levels and the plasma NO levels
were increased due to diabetes. The GSH and NO
levels in the plasma and the GSH levels in the brain
tissue of the treatment group were lower than in the
diabetic group (Tables 4 and 5). The ELISA results
indicated that diabetes caused a significant decrease
in plasma insulin concentrations (Table 5), and this
was significantly (P < 0.001) reversed by the oral
supplementation of lycopene. The lipid peroxidation
(MDA) levels were significantly increased in

both the brain tissue and the blood samples of the
diabetic group compared to the control group. This
increase had been significantly (P < 0.005) lowered
by the lycopene supplementation in the brain
tissue samples, but there was no significant effect of
lycopene in the blood samples. The SOD, CAT, and
GSH-Px activities in the erythrocytes were increased
in the diabetic + lycopene group (Table 6). The GSHPx, SOD, and CAT activities were significantly (P <
0.005) increased in the brain tissues of the diabetic
group compared to the control, but the lycopene
administration did not have any significant effect in
lowering the activities of the enzymes to the levels of
the control group.

Table 3. Plasma glucose concentrations (mg/dL; mean ± standard error).
Day

Control group

Diabetic group

Diabetic group + lycopene

Lycopene group

1

129.3 ± 8.7

113.8 ± 4.7

112.2 ± 5.0

133.5 ± 2.8

2

137.2 ± 7.5

448.2 ± 18.7*

469.4 ± 12.0

127.3 ± 35.9

9

89.3 ± 8.4

384.8 ± 28.2*

382.4 ± 20.5f

90.0 ± 2.8

f

16

107.7 ± 12.6

432.0 ± 46.6*

408.4 ± 36.3

114.0 ± 6.7

23

115.2 ± 5.6

407.2 ± 58.5*

336.2 ± 58.0f

118.0 ± 5.6

30

94.8 ± 4.5

398.2 ± 50.6*

251.4 ± 27.0

99.1 ± 5.8

f

37

103.0 ± 7.2

386.4 ± 46.7*

244.2 ± 15.5

104.0 ± 5.2

44

97.3 ± 4.2

408.4 ± 28.4*

274.8 ± 23.5f

97.0 ± 3.8

51

81.8 ± 16.2

408.2 ± 52.2*

#

249.8 ± 35.8

96.3 ± 5.0

58

103.5 ± 3.3

424.2 ± 37.5*

331.2 ± 38.6f

94.7 ± 3.5

f

*P < 0.001 compared to the control. #P < 0.05, fP < 0.001 compared to the STZ-diabetic group.
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Table 4. Effect of lycopene administration on the glutathione peroxidase (GPx), glutathione (GSH), malondialdehyde (MDA),
superoxide dismutase (SOD), and catalase (CAT) in brain tissue samples (mean ± standard error).
Control

Diabetic group

Diabetic group + lycopene

Lycopene group

GSH-Px (U/mg protein)

0.94 ± 0.039

1.37 ± 0.045*

1.77 ± 0.061f

1.17 ± 0.037*,#

GSH (nmol/g protein)

477.85 ± 7.69

496.50 ± 3.13*

428.79 ± 4.93

MDA (nmol/g protein)

4.9 ± 0.14

6.93 ± 0.2*

5.17 ± 0.085f

7.02 ± 0.2*, f

SOD (U/mg protein)

2.39 ± 0.14

2.90 ± 0.005*

2.94 ± 0.11

2.52 ± 0.11*,#

CAT (k/g protein)

0.17 ± 0.012

0.25 ± 0.014*

0.26 ± 0.012#

f

#

488.97 ± 3.78#

0.22 ± 0.016*,#

*P < 0.005 compared to the control. #P < 0.05, fP < 0.005 compared to the STZ-diabetic group.

The β-actin gene is a constitutive gene that is
used for the normalization (in the basis of the band
densities) of mRNA transcription levels. In the RTPCR analyses, it was found that the CAT gene mRNA
transcription levels were suppressed by 7.6% in the
diabetic group compared to the control group; they
were stimulated in the lycopene-supplemented
diabetic group by 187.2% (P < 0.05) compared to the
diabetic group (Figure). The mRNA transcription
levels of the GSH-Px gene were suppressed by 16.8%
in the diabetic group compared to the control group,
and they were stimulated by 333.5% (P < 0.05) in the
D + L group compared to the diabetic group (Figure).
Similarly, the SOD mRNA transcription levels were
suppressed by 12.4% in the diabetic group compared
to the control, and they were stimulated by 170.1% (P
< 0.05) in the diabetic + lycopene group compared to
the diabetic group (Figure).
Discussion

significant effects of lycopene on body weight loss
(Table 2). These findings are consistent with the
studies of Mellert et al. (26), Sindhu et al. (27), and
Duzguner et al. (11). Lipolysis and gluconeogenesis
are the 2 main reasons for weight loss during diabetes
(27,28). Diabetes-increased blood glucose levels were
suppressed by the lycopene during the 8-week period
(Table 3). Similarly, Duzguner et al. (11) determined
that during 3 weeks of lycopene administration, the
blood glucose levels in diabetic rats were decreased.
Diabetes caused a significant decrease in the
plasma insulin concentration (Table 5) due to the
damage caused by the cytotoxic effects of STZ in
the pancreatic β cells. This was reversed by the oral
administration of lycopene. It can be concluded that
the induction of free radicals caused a dysfunction
of pancreatic β cells and resulted in the reduction of
insulin secretion. Lycopene decreases oxidative stress
and the damage on essential components of the cells
such as lipids, proteins, and DNA by capturing and
reducing free radicals (29,30).

This study indicated that diabetes caused a significant
decrease in body weight; however, there were no

Lipid peroxidation (MDA) levels were significantly
increased by diabetes. This finding is in agreement

Table 5. Effect of lycopene administration on plasma MDA, NO, GSH, and insulin in blood/serum samples (mean ± standard error).
Control

Diabetic group

Diabetic group + lycopene

Lycopene group

MDA (µmol/mL)

3.16 ± 0.17

19.38 ± 0.55*

20.22 ± 0.45f

23.79 ± 0.52*,#

NO (µmol/L)

37.94 ± 0.75

61.32 ± 0.90*

53.45 ± 1.20

66.70 ± 0.96*,#

GSH (nmol/mL)

652.86 ± 8.67

664.14 ± 9.34¥

654.47 ± 11.18#

703.91 ± 5.88¥,#

Insulin (ng/mL)

4.28 ± 0.83

0.12 ± 0.02*

1.91 ± 0.22

4.16 ± 0.71¥,f

f

f

*P < 0.001, ¥P < 0.05 compared to the control. fP < 0.001, #P < 0.05 compared to the STZ-diabetic group.
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Table 6. Effect of lycopene administration on red blood cell GPx, SOD, and CAT (mean ± standard error).
Control

Diabetic group

Diabetic group + lycopene

Lycopene group

CAT (k/g Hb)

4.21 ± 0.61

8.89 ± 0.64*

11.94 ± 0.92f

8.90 ± 0.69#

GSH-Px (U/g Hb)

0.83 ± 0.016

0.68 ± 0.023¥

1.03 ± 0.054f

SOD (U/g Hb)

118.74 ± 6.89

215.58 ± 8.23*

248.42 ± 5.69

0.94 ± 0.035f
f

150.55 ± 4.39f

*P < 0.001, ¥P < 0.01 compared to the control. fP < 0.005, #P < 0.05 compared to the STZ-diabetic group.

Proportional gene expressions

with the findings of Duzguner et al. (11). Dixon et
al. (31) noted that carotenoids can significantly
decrease plasma MDA levels. This finding is not in
agreement with the results of the present study. It
was determined that lycopene caused a significant
decrease of MDA levels in the brain tissues, but not
in the plasma (Tables 4 and 5). The increase in NO
formation may play a role in the damage of the β cells
during the development of diabetes (32). Seven et al.
(33) determined that the plasma GSH concentration
of STZ-induced diabetic rats increased compared
to the control group. Similarly, this study showed
that both the NO and GSH levels in the plasma and
the GSH levels in brain tissue of the diabetic group

12
11
10
9
8
7
6
5
4
3
2
1
0

C

*

D

*

D+L
L

*

CAT

GSH-Px
Genes

SOD

Figure. Proportional gene expression levels of the CAT,
GSH-Px, and SOD genes obtained from brain tissues
(normalization process based on the average density
values of the PCR product bands that were obtained on
agarose gel and the density of the target gene, i.e. SOD,
CAT, and GSH-Px, proportioned to the density of the
control gene, β-actin). *P < 0.05 compared with the
STZ-diabetic group. C: control group, D: diabetic group,
D + L: lycopene-supplemented diabetic group, and L:
lycopene-supplemented control group.

were elevated compared to the control group. These
increases were lowered in the treatment group
compared to the diabetic group (Tables 4 and 5). The
SOD activities showed no alterations in the plasma
samples or the brain tissue samples among diabetic
and treatment groups. This finding is consistent with
that of Sindhu et al. (27). Additionally, Sindhu et al.
(27) suggested that hyperglycemia is able to generate
ROS, which can either inhibit or have no effect on
antioxidant enzyme activities (i.e. SOD). The mRNA
transcription levels of the antioxidant enzymes
(SOD, CAT, and GSH-Px) were down-regulated
by diabetes, and all of them were up-regulated by
lycopene administration.
It was demonstrated that diabetes mellitus caused
oxidative damage and lipid peroxidation in the brain
tissue and decreased the plasma insulin levels, and
these effects were significantly ameliorated by the
lycopene administrations. The results suggested that
lycopene has a significant role in silencing diabetic
disorders by its antioxidative effects.
It is concluded that lycopene treatment should be
considered in the treatment of diabetic complications
and hyperglycemia. Lycopene supplementation
can be beneficial for humans in order to reduce the
harmful effects of diabetes, such as oxidative damage
and decreased plasma insulin concentrations and
blood glucose levels.
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